• LAST PRICE
    15.4400
  • TODAY'S CHANGE (%)
    Trending Down-0.3600 (-2.2785%)
  • Bid / Lots
    14.8800/ 1
  • Ask / Lots
    16.2000/ 2
  • Open / Previous Close
    15.7600 / 15.8000
  • Day Range
    Low 15.4100
    High 15.8500
  • 52 Week Range
    Low 13.5200
    High 20.3100
  • Volume
    321,542
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 15.8
TimeVolumeRCUS
09:32 ET536515.85
09:33 ET61115.74
09:35 ET90015.755
09:37 ET20015.755
09:42 ET95015.44
09:44 ET908115.5125
09:46 ET169115.4825
09:50 ET583715.635
09:51 ET203215.685
09:53 ET382515.69
09:55 ET60015.69
09:57 ET24815.68
10:00 ET160415.635
10:02 ET98915.625
10:04 ET500715.65
10:06 ET80015.7
10:08 ET20015.68
10:09 ET141915.6
10:11 ET10015.605
10:13 ET200615.71
10:15 ET128115.705
10:18 ET28915.66
10:20 ET10015.665
10:22 ET25015.655
10:24 ET53115.54
10:26 ET80015.555
10:27 ET253815.52
10:29 ET45015.565
10:31 ET30015.57
10:33 ET533415.605
10:36 ET57315.605
10:38 ET53115.59
10:40 ET35115.555
10:44 ET51315.54
10:45 ET40015.6
10:47 ET80015.65
10:49 ET80115.69
10:51 ET112515.715
10:54 ET10015.71
10:56 ET82315.71
10:58 ET30015.72
11:00 ET39515.7
11:02 ET38915.705
11:03 ET42815.695
11:05 ET20015.695
11:07 ET260615.74
11:09 ET24115.725
11:12 ET10015.7001
11:14 ET60515.67
11:16 ET189715.63
11:18 ET41415.61
11:20 ET70515.57
11:21 ET20015.57
11:23 ET115515.635
11:25 ET70415.61
11:27 ET10015.65
11:30 ET47815.61
11:32 ET53115.61
11:34 ET10015.59
11:36 ET237615.59
11:38 ET10015.6
11:39 ET10015.58
11:41 ET10015.59
11:43 ET53415.62
11:45 ET10015.635
11:48 ET53215.59
11:50 ET10015.605
11:52 ET97415.625
11:54 ET20015.625
11:56 ET10015.63
11:57 ET70015.61
11:59 ET44515.61
12:01 ET98815.625
12:03 ET10015.625
12:08 ET73915.66
12:10 ET323415.615
12:12 ET89115.57
12:14 ET122315.55
12:15 ET100015.55
12:17 ET52315.53
12:19 ET327315.54
12:21 ET275615.59
12:24 ET102115.61
12:26 ET560915.695
12:28 ET65015.695
12:30 ET83315.68
12:32 ET212415.615
12:33 ET50015.59
12:35 ET165815.59
12:37 ET318115.57
12:39 ET96415.585
12:42 ET192215.585
12:44 ET184915.59
12:46 ET233715.605
12:48 ET232615.55
12:50 ET150015.575
12:51 ET276415.48
12:53 ET274215.525
12:55 ET406815.49
12:57 ET355515.47
01:00 ET10127215.44
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRCUS
Arcus Biosciences Inc
1.4B
-4.9x
---
United StatesARDX
Ardelyx Inc
1.3B
-18.2x
---
United StatesNRIX
Nurix Therapeutics Inc
1.5B
-7.6x
---
United StatesTVTX
Travere Therapeutics Inc
1.6B
-4.2x
---
United StatesGYRE
Gyre Therapeutics Inc
1.1B
-54.8x
---
United StatesARQT
Arcutis Biotherapeutics Inc
1.3B
-7.3x
---
As of 2024-12-02

Company Information

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Contact Information

Headquarters
3928 Point Eden WayHAYWARD, CA, United States 94545-3719
Phone
510-694-6200
Fax
302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Terry Rosen
President, Co-Founder
Juan Jaen
Chief Financial Officer
Robert Goeltz
Chief Operating Officer
Jennifer Jarrett
General Counsel
Carolyn Tang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.4B
Revenue (TTM)
$263.0M
Shares Outstanding
91.5M
Arcus Biosciences Inc does not pay a dividend.
Beta
0.87
EPS
$-3.15
Book Value
$6.12
P/E Ratio
-4.9x
Price/Sales (TTM)
5.5
Price/Cash Flow (TTM)
---
Operating Margin
-120.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.